# SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma

> **NCT07744932** · PHASE2 · RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Oligometastatic Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** axitinib plus toripalimab
- **RADIATION:** SABR

## Key facts

- **NCT ID:** NCT07744932
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-15
- **Primary completion:** 2027-12-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07744932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07744932, "SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07744932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*